董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edward L. Michael | 男 | Independent Director | 69 | 32.40万美元 | 2.63 | 2026-06-30 |
| Joseph D. Wilkins Jr. | 男 | Independent Director | 64 | 28.50万美元 | 1.15 | 2026-06-30 |
| Kenneth F. Buechler | 男 | Chair of the Board and Independent Director | 72 | 42.45万美元 | 12.89 | 2026-06-30 |
| Mary Lake Polan | 女 | Independent Director | 82 | 30.75万美元 | 3.91 | 2026-06-30 |
| R. Scott Huennekens | 男 | Independent Director | 62 | 30.11万美元 | 0.25 | 2026-06-30 |
| Ann D. Rhoads | 女 | Independent Director | 61 | 32.00万美元 | 1.57 | 2026-06-30 |
| Evelyn Dilsaver | 女 | Independent Director | 70 | 28.50万美元 | 1.06 | 2026-06-30 |
| Brian J. Blaser | 男 | President, Chief Executive Officer and Director | 61 | 1125.58万美元 | 2.08 | 2026-06-30 |
| Kenneth J. Widder | 男 | Independent Director | 73 | 32.70万美元 | 5.09 | 2026-06-30 |
| John R. Chiminski | 男 | Independent Director | 62 | 31.61万美元 | 0.25 | 2026-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michelle A. Hodges | 女 | Chief Legal Officer | 66 | 350.81万美元 | 4.10 | 2026-06-30 |
| Lee Bowman | 男 | Chief Human Resources Officer | 46 | 未披露 | 未持股 | 2026-06-30 |
| Philip D. McLellan | 男 | Chief Operations Officer | 56 | 202.20万美元 | 2.83 | 2026-06-30 |
| Jonathan P. Siegrist | 男 | Executive Vice President of R&D and Chief Technology Officer | 43 | 179.11万美元 | 未持股 | 2026-06-30 |
| Brian J. Blaser | 男 | President, Chief Executive Officer and Director | 61 | 1125.58万美元 | 2.08 | 2026-06-30 |
董事简历
中英对照 | 中文 | 英文- Edward L. Michael
-
Edward L. Michael。2008年至今担任Diagnostic Products的执行副总裁。2007至2008年，担任Diagnostics的执行副总裁。2007年，担任Medical Products的高级副总裁。2007年，担任Medical Products的高级副总裁。1997年，担任选举的公司官员。
Edward L. Michael,held a variety of roles at Abbott Laboratories, including most recently as Executive Vice President, Diagnostic Products and previously in legal, commercial and operational roles in various Abbott divisions. Mr. Michael currently serves on the boards of directors of certain private LionBird portfolio companies. Mr. Michael received his B.A. from Indiana University and a J.D. from Indiana University School of Law. - Edward L. Michael。2008年至今担任Diagnostic Products的执行副总裁。2007至2008年，担任Diagnostics的执行副总裁。2007年，担任Medical Products的高级副总裁。2007年，担任Medical Products的高级副总裁。1997年，担任选举的公司官员。
- Edward L. Michael,held a variety of roles at Abbott Laboratories, including most recently as Executive Vice President, Diagnostic Products and previously in legal, commercial and operational roles in various Abbott divisions. Mr. Michael currently serves on the boards of directors of certain private LionBird portfolio companies. Mr. Michael received his B.A. from Indiana University and a J.D. from Indiana University School of Law.
- Joseph D. Wilkins Jr.
-
Joseph D. Wilkins Jr.于2021年2月被任命为董事会成员。自2019年以来，威尔金斯先生一直担任医疗保健0 Insights（医疗保健咨询公司）的董事总经理。他还是私人风险投资基金Tech Council Ventures的有限合伙人，以及私人风险投资集团Touchdown Ventures的顾问。此前，从2018年至2019年，威尔金斯先生担任医疗保健咨询公司TRG 医疗保健的合伙人。2016年至2018年，威尔金斯先生担任综合医疗保健提供系统Atlantic Health System的高级副总裁兼首席转型/创新官。在此之前，威尔金斯先生领导过Quest Diagnostics的商业运营团队，在此之前，他曾在Danaher-Beckman Coulter担任过各种职务约28年。Wilkins先生目前还在Mazzetti的董事会任职，这是一家私人持有的工程和设计福利公司。威尔金斯先生在阿戈西大学获得学士学位和工商管理硕士学位，是美国医疗保健主管学院的董事会认证会员。
Joseph D. Wilkins Jr.,served as Senior Vice President and Chief Transformation and Innovation Officer for Atlantic Health System, an integrated healthcare delivery system, from October 2016 to October 2018. Prior to that, Mr. Wilkins led commercial operations teams at Quest Diagnostics. He also held various executive leadership roles at Danaher-Beckman Coulter for approximately 28 years. Mr. Wilkins serves on the board of directors of Providence Health and Services, one of the nation's largest healthcare systems, and the board of TGR Foundation, founded by Tiger Woods. Mr. Wilkins earned a B.A. and an M.B.A. in healthcare finance from Argosy University, is board-certified in healthcare management and serves as a Fellow of the American College of Healthcare Executives. - Joseph D. Wilkins Jr.于2021年2月被任命为董事会成员。自2019年以来，威尔金斯先生一直担任医疗保健0 Insights（医疗保健咨询公司）的董事总经理。他还是私人风险投资基金Tech Council Ventures的有限合伙人，以及私人风险投资集团Touchdown Ventures的顾问。此前，从2018年至2019年，威尔金斯先生担任医疗保健咨询公司TRG 医疗保健的合伙人。2016年至2018年，威尔金斯先生担任综合医疗保健提供系统Atlantic Health System的高级副总裁兼首席转型/创新官。在此之前，威尔金斯先生领导过Quest Diagnostics的商业运营团队，在此之前，他曾在Danaher-Beckman Coulter担任过各种职务约28年。Wilkins先生目前还在Mazzetti的董事会任职，这是一家私人持有的工程和设计福利公司。威尔金斯先生在阿戈西大学获得学士学位和工商管理硕士学位，是美国医疗保健主管学院的董事会认证会员。
- Joseph D. Wilkins Jr.,served as Senior Vice President and Chief Transformation and Innovation Officer for Atlantic Health System, an integrated healthcare delivery system, from October 2016 to October 2018. Prior to that, Mr. Wilkins led commercial operations teams at Quest Diagnostics. He also held various executive leadership roles at Danaher-Beckman Coulter for approximately 28 years. Mr. Wilkins serves on the board of directors of Providence Health and Services, one of the nation's largest healthcare systems, and the board of TGR Foundation, founded by Tiger Woods. Mr. Wilkins earned a B.A. and an M.B.A. in healthcare finance from Argosy University, is board-certified in healthcare management and serves as a Fellow of the American College of Healthcare Executives.
- Kenneth F. Buechler
-
Kenneth F. Buechler，他是哲学博士。他一直担任董事（自2007年以来）。他曾担任Biosite Incorporated公司的总裁、首席科学官和共同创始人。从1988年到1994年，他担任Biosite公司的化学董事。共同创立Biosite公司之前，他曾担任Hybritech Incorporated公司的诊断研发部门的高级研究科学家。他持有Indiana University的生物化学博士学位和化学学士学位。他也是Sequenom公司、Sotera Wireless公司、Astute Medical公司、Edico Genome公司的董事。
Kenneth F. Buechler,was previously the co-founder of and held various roles at Biosite Inc. from 1988 until its acquisition by Alere Inc. in 2007, including serving as a director and as President and Chief Scientific Officer, Senior Vice President, Research and Development, and Vice President, Research and Director of Chemistry. Prior to co-founding Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Inc. Dr. Buechler currently serves as a director of TriVirum, Inc., and previously served as chair of the board of directors of Sequenom Inc., a life sciences company until its acquisition in September 2016, Astute Medical Inc., a company that develops biomarkers for acute medical conditions until its acquisition in April 2018, and Edico Genome Inc., a DNA sequencing technology company until its acquisition in May 2018. Dr. Buechler received his Ph.D. in Biochemistry and his Bachelor's Degree in Chemistry from Indiana University. - Kenneth F. Buechler，他是哲学博士。他一直担任董事（自2007年以来）。他曾担任Biosite Incorporated公司的总裁、首席科学官和共同创始人。从1988年到1994年，他担任Biosite公司的化学董事。共同创立Biosite公司之前，他曾担任Hybritech Incorporated公司的诊断研发部门的高级研究科学家。他持有Indiana University的生物化学博士学位和化学学士学位。他也是Sequenom公司、Sotera Wireless公司、Astute Medical公司、Edico Genome公司的董事。
- Kenneth F. Buechler,was previously the co-founder of and held various roles at Biosite Inc. from 1988 until its acquisition by Alere Inc. in 2007, including serving as a director and as President and Chief Scientific Officer, Senior Vice President, Research and Development, and Vice President, Research and Director of Chemistry. Prior to co-founding Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Inc. Dr. Buechler currently serves as a director of TriVirum, Inc., and previously served as chair of the board of directors of Sequenom Inc., a life sciences company until its acquisition in September 2016, Astute Medical Inc., a company that develops biomarkers for acute medical conditions until its acquisition in April 2018, and Edico Genome Inc., a DNA sequencing technology company until its acquisition in May 2018. Dr. Buechler received his Ph.D. in Biochemistry and his Bachelor's Degree in Chemistry from Indiana University.
- Mary Lake Polan
-
Mary Lake Polan自2004年2月一直担任公司的非执行董事。Polan博士是2014年以来耶鲁大学医学院系产科，妇科，生殖和科学医学院的临床教授。从2008至2014年Polan博士担任哥伦比亚大学医学院妇产科系兼职教授。1990年至2006年她曾担任斯坦福大学医学院妇产科的系主任和名誉教授。Polan博士专门从事生殖内分泌和不孕不育及相关妇科患者和更年期荷尔蒙的问题。Polan博士担任惠氏（Wyeth）（NYSE：WYE）的董事会成员（1995-2009），其收购Pfizer Inc.，目前是Quidel Corp.（NASDAQ： QDEL）的董事（自1993年），并在几个私人持有的生命科学公司担任董事会成员。她主持的妇女健康科学顾问委员会为宝洁公司和私人生命科学公司的其他几个顾问委员会成员。她还担任Golden Seeds常务董事，投资于妇女的天使投资集团牵头的企业。她从康涅狄格学院获得学士学位，生物物理与生物化学分子哲学博士，从耶鲁大学医学博士，并从耶鲁大学部妇产科医学院获得了她的居住和生殖内分泌奖学金。Polan博士持有加州大学伯克利分校（the Fisher Center Policy Advisory Board）的公共卫生硕士学位（妇幼卫生项目）。
Mary Lake Polan,served as a Professor and Chair Emerita of the Department of Gynecology and Obstetrics at Stanford University School of Medicine from 1990 to 2005, and before that served on the faculty at Yale University. Dr. Polan received a B.A. degree from Connecticut College, a Ph.D. in Molecular Biophysics and Biochemistry and an M.D. from Yale University School of Medicine and her M.P.H. from the University of California, Berkeley. Dr. Polan remained at Yale New Haven Hospital for her residency in Obstetrics and Gynecology, followed by a Reproductive Endocrine Fellowship. Dr. Polan also serves as a director at the following private companies: NX Prenatal Inc., Or-Genix Therapeutics, Inc., Residents Diagnostics, Inc. and MiraDx, Inc. - Mary Lake Polan自2004年2月一直担任公司的非执行董事。Polan博士是2014年以来耶鲁大学医学院系产科，妇科，生殖和科学医学院的临床教授。从2008至2014年Polan博士担任哥伦比亚大学医学院妇产科系兼职教授。1990年至2006年她曾担任斯坦福大学医学院妇产科的系主任和名誉教授。Polan博士专门从事生殖内分泌和不孕不育及相关妇科患者和更年期荷尔蒙的问题。Polan博士担任惠氏（Wyeth）（NYSE：WYE）的董事会成员（1995-2009），其收购Pfizer Inc.，目前是Quidel Corp.（NASDAQ： QDEL）的董事（自1993年），并在几个私人持有的生命科学公司担任董事会成员。她主持的妇女健康科学顾问委员会为宝洁公司和私人生命科学公司的其他几个顾问委员会成员。她还担任Golden Seeds常务董事，投资于妇女的天使投资集团牵头的企业。她从康涅狄格学院获得学士学位，生物物理与生物化学分子哲学博士，从耶鲁大学医学博士，并从耶鲁大学部妇产科医学院获得了她的居住和生殖内分泌奖学金。Polan博士持有加州大学伯克利分校（the Fisher Center Policy Advisory Board）的公共卫生硕士学位（妇幼卫生项目）。
- Mary Lake Polan,served as a Professor and Chair Emerita of the Department of Gynecology and Obstetrics at Stanford University School of Medicine from 1990 to 2005, and before that served on the faculty at Yale University. Dr. Polan received a B.A. degree from Connecticut College, a Ph.D. in Molecular Biophysics and Biochemistry and an M.D. from Yale University School of Medicine and her M.P.H. from the University of California, Berkeley. Dr. Polan remained at Yale New Haven Hospital for her residency in Obstetrics and Gynecology, followed by a Reproductive Endocrine Fellowship. Dr. Polan also serves as a director at the following private companies: NX Prenatal Inc., Or-Genix Therapeutics, Inc., Residents Diagnostics, Inc. and MiraDx, Inc.
- R. Scott Huennekens
-
R. Scott Huennekens，2002年4月起，担任本公司的总裁、首席执行官、董事。2000年1月至2002年3月，他是医学影像公司Digirad Corporation的总裁、首席执行官。他目前是 Medical Device Manufacturers Association MDMA的董事，这是一个全国性的行业协会。
R. Scott Huennekens,most recently served as the interim President and CEO of Hyperfine, Inc., a medical technology company focused on creating access to life-saving diagnostics and actionable data at the point of care, from June 2022 to October 2022.From August 2015 to December 2018, Mr. Huennekens served as the President, Chief Executive Officer and Chairman of the Board of Verb Surgical, a start-up company formed by Google and Johnson & Johnson to develop an advanced digital surgery platform. Prior to joining Verb Surgical, Mr. Huennekens was the President, Chief Executive Officer and a member of the Board of Directors of Volcano Corporation, a medical technology company focused on diagnostic and therapeutic solutions for coronary and peripheral artery disease, from 2002 until Volcano was acquired by Royal Philips in February 2015. Prior to joining Volcano, Mr. Huennekens served as the President and Chief Executive Officer of Digirad Corporation, a diagnostic imaging solutions provider, and previously served as its Chief Financial Officer. - R. Scott Huennekens，2002年4月起，担任本公司的总裁、首席执行官、董事。2000年1月至2002年3月，他是医学影像公司Digirad Corporation的总裁、首席执行官。他目前是 Medical Device Manufacturers Association MDMA的董事，这是一个全国性的行业协会。
- R. Scott Huennekens,most recently served as the interim President and CEO of Hyperfine, Inc., a medical technology company focused on creating access to life-saving diagnostics and actionable data at the point of care, from June 2022 to October 2022.From August 2015 to December 2018, Mr. Huennekens served as the President, Chief Executive Officer and Chairman of the Board of Verb Surgical, a start-up company formed by Google and Johnson & Johnson to develop an advanced digital surgery platform. Prior to joining Verb Surgical, Mr. Huennekens was the President, Chief Executive Officer and a member of the Board of Directors of Volcano Corporation, a medical technology company focused on diagnostic and therapeutic solutions for coronary and peripheral artery disease, from 2002 until Volcano was acquired by Royal Philips in February 2015. Prior to joining Volcano, Mr. Huennekens served as the President and Chief Executive Officer of Digirad Corporation, a diagnostic imaging solutions provider, and previously served as its Chief Financial Officer.
- Ann D. Rhoads
-
Ann D. Rhoads， 自2010年3月起担任执行副总裁、首席财务官和风险官、以及秘书的职位。2000年到2009年12月担任Premier, Inc.（一家医疗保健服务公司）首席财务官，负责金融管理、战略规划、业务开发、信息技术和道德与合规的所有事项。1998年8月到2000年担任Premier战略活动副总裁，负责监管战略投资，包括风险资本基金以及协助Premier的运营部门提供长期战略规划。加入Premier之前，她在Sprout Group（Donaldson, Lufkin & Jenrette的风险资本附属公司，现在是Credit Suisse First Boston, Bain & Company 和 Merrill Lynch Capital Partners的一部份。 Merrill Lynch Capital Partners现名为Stonington Partners） 担任多个职位。她现在是 Globus Medical Inc.和 Evoke Pharma, Inc.董事。她持有Arkansas大学理学学士学位和哈佛商学院（the Harvard Business School。）工商管理硕士学位。
Ann D. Rhoads,served as Chief Financial Officer of Forty Seven, Inc., a formerly publicly-traded biotechnology company, from March 2018 to June 2020. Previously, Ms. Rhoads was the Executive Vice President and Chief Financial Officer of Zogenix, Inc., a formerly publicly-traded pharmaceutical company, from 2010 to January 2017. From 2000 to the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was the Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was an investment professional with The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from Harvard Business School. - Ann D. Rhoads， 自2010年3月起担任执行副总裁、首席财务官和风险官、以及秘书的职位。2000年到2009年12月担任Premier, Inc.（一家医疗保健服务公司）首席财务官，负责金融管理、战略规划、业务开发、信息技术和道德与合规的所有事项。1998年8月到2000年担任Premier战略活动副总裁，负责监管战略投资，包括风险资本基金以及协助Premier的运营部门提供长期战略规划。加入Premier之前，她在Sprout Group（Donaldson, Lufkin & Jenrette的风险资本附属公司，现在是Credit Suisse First Boston, Bain & Company 和 Merrill Lynch Capital Partners的一部份。 Merrill Lynch Capital Partners现名为Stonington Partners） 担任多个职位。她现在是 Globus Medical Inc.和 Evoke Pharma, Inc.董事。她持有Arkansas大学理学学士学位和哈佛商学院（the Harvard Business School。）工商管理硕士学位。
- Ann D. Rhoads,served as Chief Financial Officer of Forty Seven, Inc., a formerly publicly-traded biotechnology company, from March 2018 to June 2020. Previously, Ms. Rhoads was the Executive Vice President and Chief Financial Officer of Zogenix, Inc., a formerly publicly-traded pharmaceutical company, from 2010 to January 2017. From 2000 to the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was the Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was an investment professional with The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from Harvard Business School.
- Evelyn Dilsaver
-
Evelyn Dilsaver，自2009年12月起担任丹普西利国际董事会成员。Dilsaver女士于2004年7月至2007年9月担任Charles Schwab投资管理公司总裁兼首席执行官。在此之前，Dilsaver女士自1991年12月起在嘉信理财公司担任多个高级管理职务，包括Charles Schwab投资管理公司执行副总裁兼资产管理产品和服务高级副总裁以及美国信托公司首席财务官。Dilsaver女士还是HealthEquity，Inc. HQY、非银行健康储蓄受托人、Bailard Private Real Estate Fund、Blue Shield of California以及多个非营利委员会的董事会成员。她还担任全球咨询公司Protiviti Inc.的顾问委员会成员。在过去五年中，Dilsaver女士还担任过专业零售商Aeropostale的董事。Dilsaver女士是一名注册会计师，拥有加州州立大学海沃德分校会计学学士学位。
Evelyn Dilsaver has served as a member of board of directors since 2014. Ms. Dilsaver is a member of the board of directors and chair of the audit committee of Tempur Sealy International, Inc. (NYSE: TPX), a member of the board of directors of QuidelOrtho Corporation (NASDAQ: QDEL), and a member of the board of directors of PACS Group, Inc. (NYSE: PACS). Ms. Dilsaver previously served as a director of Aéropostale Inc. (NYSE: ARO), HighMark Funds, Russell Exchange Traded Funds, Longs Drug Stores Corp. and Tamalpais Bancorp. She is also a member of the board of directors of a privately held corporation and real estate investment trust. Ms. Dilsaver was formerly a member of The Charles Schwab Corporation from 1991 until her retirement in 2007. During her tenure at The Charles Schwab Corporation, Ms. Dilsaver held various senior management positions within the organization, including Executive Vice President (The Charles Schwab Corporation) and President and Chief Executive Officer (Charles Schwab Investment Management). Prior to becoming President and Chief Executive Officer of Charles Schwab Investment Management, a position she held from 2003 to 2007, Ms. Dilsaver held the position of Senior Vice President, Asset Management Products and Services. - Evelyn Dilsaver，自2009年12月起担任丹普西利国际董事会成员。Dilsaver女士于2004年7月至2007年9月担任Charles Schwab投资管理公司总裁兼首席执行官。在此之前，Dilsaver女士自1991年12月起在嘉信理财公司担任多个高级管理职务，包括Charles Schwab投资管理公司执行副总裁兼资产管理产品和服务高级副总裁以及美国信托公司首席财务官。Dilsaver女士还是HealthEquity，Inc. HQY、非银行健康储蓄受托人、Bailard Private Real Estate Fund、Blue Shield of California以及多个非营利委员会的董事会成员。她还担任全球咨询公司Protiviti Inc.的顾问委员会成员。在过去五年中，Dilsaver女士还担任过专业零售商Aeropostale的董事。Dilsaver女士是一名注册会计师，拥有加州州立大学海沃德分校会计学学士学位。
- Evelyn Dilsaver has served as a member of board of directors since 2014. Ms. Dilsaver is a member of the board of directors and chair of the audit committee of Tempur Sealy International, Inc. (NYSE: TPX), a member of the board of directors of QuidelOrtho Corporation (NASDAQ: QDEL), and a member of the board of directors of PACS Group, Inc. (NYSE: PACS). Ms. Dilsaver previously served as a director of Aéropostale Inc. (NYSE: ARO), HighMark Funds, Russell Exchange Traded Funds, Longs Drug Stores Corp. and Tamalpais Bancorp. She is also a member of the board of directors of a privately held corporation and real estate investment trust. Ms. Dilsaver was formerly a member of The Charles Schwab Corporation from 1991 until her retirement in 2007. During her tenure at The Charles Schwab Corporation, Ms. Dilsaver held various senior management positions within the organization, including Executive Vice President (The Charles Schwab Corporation) and President and Chief Executive Officer (Charles Schwab Investment Management). Prior to becoming President and Chief Executive Officer of Charles Schwab Investment Management, a position she held from 2003 to 2007, Ms. Dilsaver held the position of Senior Vice President, Asset Management Products and Services.
- Brian J. Blaser
-
Brian J. Blaser，2012年-至今，他担任负责诊断产品的高级副总裁兼首席财务官。2010年至2012年，他担任负责诊断的高级副总裁。2008年至2010年，负责诊断的副总裁。2008年，他被当选为企业主管。
Brian J. Blaser,2012 to present - Executive Vice President, Diagnostics Products. 2010 to 2012 - Senior Vice President, Diagnostics. Elected Corporate Officer - 2008. - Brian J. Blaser，2012年-至今，他担任负责诊断产品的高级副总裁兼首席财务官。2010年至2012年，他担任负责诊断的高级副总裁。2008年至2010年，负责诊断的副总裁。2008年，他被当选为企业主管。
- Brian J. Blaser,2012 to present - Executive Vice President, Diagnostics Products. 2010 to 2012 - Senior Vice President, Diagnostics. Elected Corporate Officer - 2008.
- Kenneth J. Widder
-
Kenneth J. Widder医学博士 自2007年6月起，他便担任公司董事会成员。他在生物医药公司工作32多年。自2007年起，他一直是Latterell Venture Partners公司普通合伙人。并担任以下公司董事会成员：Meritage制药公司，Naurex公司，儿童视野公司，圣地亚哥艺术博物馆。他创立了七家公司，并作为其中五家公司的主席兼首席执行官。他创立的最后一家公司，Sytera公司和西连治疗公司（一家专业眼科制药公司）合并。在加入Sytera公司之前，由他共同创办了NovaCardia公司（该公司后来和默克公司合并），并担任最初的首席执行官。在加入NovaCardia公司之前，他创立了Santarus公司（该公司于日前被萨柳医药以26亿美元收购）并任董事长兼首席执行官。此外，他还任Converge医药公司（一家开发冠状动脉静脉移植搭桥手术无缝技术医疗器械公司）的董事长兼首席执行官。作为分子生物系统公司创始人、董事长兼首席执行官开始了他的职业生涯。在那里，他负责Albunex Optison公司的开发及获批，这是美国最早两个获批的超声造影剂公司。他有着30多项专利，及他是专利申请的发明人，并已撰写或合作撰写了超过25部出版物。他拥有美国西北大学的医学博士学位，并在杜克大学接受了病理学培训。
Kenneth J. Widder,has more than 30 years of experience working with biomedical companies. Dr. Widder previously served as the Executive Chair of OrphoMed Inc., a clinical-stage biopharmaceutical company, from 2017 to 2022, and board Chair and Chief Executive Officer of Sydnexis, Inc., an ophthalmology start-up company, from 2017 to 2022. Dr. Widder was a General Partner with LVP Life Science Ventures, a venture capital company for biotechnology and medical device start-ups, from 2007 to 2016. Dr. Widder holds an M.D. from Northwestern University and trained in pathology at Duke University. - Kenneth J. Widder医学博士 自2007年6月起，他便担任公司董事会成员。他在生物医药公司工作32多年。自2007年起，他一直是Latterell Venture Partners公司普通合伙人。并担任以下公司董事会成员：Meritage制药公司，Naurex公司，儿童视野公司，圣地亚哥艺术博物馆。他创立了七家公司，并作为其中五家公司的主席兼首席执行官。他创立的最后一家公司，Sytera公司和西连治疗公司（一家专业眼科制药公司）合并。在加入Sytera公司之前，由他共同创办了NovaCardia公司（该公司后来和默克公司合并），并担任最初的首席执行官。在加入NovaCardia公司之前，他创立了Santarus公司（该公司于日前被萨柳医药以26亿美元收购）并任董事长兼首席执行官。此外，他还任Converge医药公司（一家开发冠状动脉静脉移植搭桥手术无缝技术医疗器械公司）的董事长兼首席执行官。作为分子生物系统公司创始人、董事长兼首席执行官开始了他的职业生涯。在那里，他负责Albunex Optison公司的开发及获批，这是美国最早两个获批的超声造影剂公司。他有着30多项专利，及他是专利申请的发明人，并已撰写或合作撰写了超过25部出版物。他拥有美国西北大学的医学博士学位，并在杜克大学接受了病理学培训。
- Kenneth J. Widder,has more than 30 years of experience working with biomedical companies. Dr. Widder previously served as the Executive Chair of OrphoMed Inc., a clinical-stage biopharmaceutical company, from 2017 to 2022, and board Chair and Chief Executive Officer of Sydnexis, Inc., an ophthalmology start-up company, from 2017 to 2022. Dr. Widder was a General Partner with LVP Life Science Ventures, a venture capital company for biotechnology and medical device start-ups, from 2007 to 2016. Dr. Widder holds an M.D. from Northwestern University and trained in pathology at Duke University.
- John R. Chiminski
-
John R. Chiminski自2009年3月担任Catalent公司总裁以及首席执行官。Chiminski先生将多样化的业务背景带到了Catalent公司，包括精实生产、供应链、研发、顾客服务以及全球业务管理，其中主中关注顾客和企业成长。他在通用电气健康护理公司担任工程、运营和高级领导职务的20多年后加入Catalent公司。从2007年到2009年，Chiminski先生担任通用电气医疗诊断公司的总裁以及首席执行官，该公司是一家年利润为19亿美元的国际公司；从2005年到2007年，他担任通用电气健康护理公司全球磁共振业务部的副总裁以及总经理；从2001年到2005年担任全球健康护理服务公司的副总裁以及总经理。再加入通用电气前，他在制造工程也担任一系列跨功能领导职务，包括在法国通用电气医疗系统公司任职。Chiminski先生从密歇根州立大学获得电气工程学士学位，从普渡大学获得电气工程学士学位，从西北大学克罗格管理学院获得管理学硕士学位。他还任职于新泽西健康护理歇会受托人委员会，同时担任DJO国际股份有限公司董事。
John R. Chiminski was appointed Catalent's Executive Chair in July 2022. Prior to that he had served as Catalent's Chief Executive Officer since 2009. He joined Catalent after more than 20 years of experience at GE Healthcare in engineering, operations, and senior leadership roles. From 2007 to 2009 Mr. Chiminski was President and Chief Executive Officer of GE Medical Diagnostics, a global business with sales of $1.9 billion. From 2005 to 2007 he served as Vice President and General Manager of GE Healthcare's Global Magnetic Resonance Business, and from 2001 to 2005 as Vice President and General Manager of Global Healthcare Services. Earlier at GE, he held a series of cross-functional leadership positions in both manufacturing and engineering, including a GE Medical Systems assignment in France. Mr. Chiminski has served as a director of Berkeley Lights since May 2021. Mr. Chiminski holds a BS from Michigan State University and an M.S. from Purdue University, both in electrical engineering, as well as a Master's Degree in Management from the Kellogg School of Management at Northwestern University. - John R. Chiminski自2009年3月担任Catalent公司总裁以及首席执行官。Chiminski先生将多样化的业务背景带到了Catalent公司，包括精实生产、供应链、研发、顾客服务以及全球业务管理，其中主中关注顾客和企业成长。他在通用电气健康护理公司担任工程、运营和高级领导职务的20多年后加入Catalent公司。从2007年到2009年，Chiminski先生担任通用电气医疗诊断公司的总裁以及首席执行官，该公司是一家年利润为19亿美元的国际公司；从2005年到2007年，他担任通用电气健康护理公司全球磁共振业务部的副总裁以及总经理；从2001年到2005年担任全球健康护理服务公司的副总裁以及总经理。再加入通用电气前，他在制造工程也担任一系列跨功能领导职务，包括在法国通用电气医疗系统公司任职。Chiminski先生从密歇根州立大学获得电气工程学士学位，从普渡大学获得电气工程学士学位，从西北大学克罗格管理学院获得管理学硕士学位。他还任职于新泽西健康护理歇会受托人委员会，同时担任DJO国际股份有限公司董事。
- John R. Chiminski was appointed Catalent's Executive Chair in July 2022. Prior to that he had served as Catalent's Chief Executive Officer since 2009. He joined Catalent after more than 20 years of experience at GE Healthcare in engineering, operations, and senior leadership roles. From 2007 to 2009 Mr. Chiminski was President and Chief Executive Officer of GE Medical Diagnostics, a global business with sales of $1.9 billion. From 2005 to 2007 he served as Vice President and General Manager of GE Healthcare's Global Magnetic Resonance Business, and from 2001 to 2005 as Vice President and General Manager of Global Healthcare Services. Earlier at GE, he held a series of cross-functional leadership positions in both manufacturing and engineering, including a GE Medical Systems assignment in France. Mr. Chiminski has served as a director of Berkeley Lights since May 2021. Mr. Chiminski holds a BS from Michigan State University and an M.S. from Purdue University, both in electrical engineering, as well as a Master's Degree in Management from the Kellogg School of Management at Northwestern University.
高管简历
中英对照 | 中文 | 英文- Michelle A. Hodges
Michelle A. Hodges于2020年12月成为我们的高级副总裁兼总法律顾问。在加入Quidel之前，Hodges女士从1996年12月至2020年11月担任Gibson，Dunn & Crutcher LLP律师事务所的公司律师，最近从2005年起担任合伙人。霍奇斯女士获得学士学位。在新西兰梅西大学获得科学学士学位，并在加州大学洛杉矶分校获得法学博士和工商管理硕士学位。
Michelle A. Hodges,was a corporate lawyer with the law firm of Gibson, Dunn & Crutcher LLP from December 1996 to November 2020, including most recently as a partner from 2005. Ms. Hodges received her J.D. and M.B.A. from UCLA and her B. Hort. Sci. degree from Massey University, New Zealand.- Michelle A. Hodges于2020年12月成为我们的高级副总裁兼总法律顾问。在加入Quidel之前，Hodges女士从1996年12月至2020年11月担任Gibson，Dunn & Crutcher LLP律师事务所的公司律师，最近从2005年起担任合伙人。霍奇斯女士获得学士学位。在新西兰梅西大学获得科学学士学位，并在加州大学洛杉矶分校获得法学博士和工商管理硕士学位。
- Michelle A. Hodges,was a corporate lawyer with the law firm of Gibson, Dunn & Crutcher LLP from December 1996 to November 2020, including most recently as a partner from 2005. Ms. Hodges received her J.D. and M.B.A. from UCLA and her B. Hort. Sci. degree from Massey University, New Zealand.
- Lee Bowman
Lee Bowman，于2022年5月至2023年11月担任影像诊断服务公司雷网的高级副总裁兼首席人事官，并于2019年至2022年担任医疗保健技术公司爱德华兹生命科学的全球人力资源高级副总裁，负责监督全球人力资源运营、组织有效性和创新。Bowman先生获得了圣地亚哥州立大学的工商管理硕士学位和陶森大学的心理学学士学位。
Lee Bowman,served as Senior Vice President and Chief People Officer of RadNet, a diagnostic imaging services company, from May 2022 to November 2023, and as Senior Vice President, Global Human Resources of Edwards Lifesciences, a healthcare technology company, from 2019 to 2022, where he oversaw global human resources operations, organizational effectiveness and innovation. Mr. Bowman received his M.B.A. from San Diego State University and his B.S. in Psychology from Towson University.- Lee Bowman，于2022年5月至2023年11月担任影像诊断服务公司雷网的高级副总裁兼首席人事官，并于2019年至2022年担任医疗保健技术公司爱德华兹生命科学的全球人力资源高级副总裁，负责监督全球人力资源运营、组织有效性和创新。Bowman先生获得了圣地亚哥州立大学的工商管理硕士学位和陶森大学的心理学学士学位。
- Lee Bowman,served as Senior Vice President and Chief People Officer of RadNet, a diagnostic imaging services company, from May 2022 to November 2023, and as Senior Vice President, Global Human Resources of Edwards Lifesciences, a healthcare technology company, from 2019 to 2022, where he oversaw global human resources operations, organizational effectiveness and innovation. Mr. Bowman received his M.B.A. from San Diego State University and his B.S. in Psychology from Towson University.
- Philip D. McLellan
Philip D. McLellan，在赛默飞世尔领导了几个不同生命科学部门的部门运营团队长达11年，包括实验室耗材、基因分析和生物生产业务。在此之前，他曾在丰田汽车制造部门担任过多个全球汽车制造职务，任职时间长达13年。McLellan先生在佐治亚理工学院获得机械工程学士学位。
Philip D. McLellan,led the division operations teams for several different life sciences divisions at Thermo Fisher Scientific for 11 years, including the Laboratory Consumables, Genetic Analysis, and Bioproduction businesses. Prior to that, he had several global automotive manufacturing roles with Toyota Motor Manufacturing for 13 years. Mr. McLellan received his B.S. in Mechanical Engineering from Georgia Institute of Technology.- Philip D. McLellan，在赛默飞世尔领导了几个不同生命科学部门的部门运营团队长达11年，包括实验室耗材、基因分析和生物生产业务。在此之前，他曾在丰田汽车制造部门担任过多个全球汽车制造职务，任职时间长达13年。McLellan先生在佐治亚理工学院获得机械工程学士学位。
- Philip D. McLellan,led the division operations teams for several different life sciences divisions at Thermo Fisher Scientific for 11 years, including the Laboratory Consumables, Genetic Analysis, and Bioproduction businesses. Prior to that, he had several global automotive manufacturing roles with Toyota Motor Manufacturing for 13 years. Mr. McLellan received his B.S. in Mechanical Engineering from Georgia Institute of Technology.
- Jonathan P. Siegrist
Jonathan P. Siegrist，自2011年起在分子诊断公司Cepheid任职期间担任多个高级研发职位，包括2023年12月至2024年10月担任首席技术官和Assay研发主管，2021年至2023年担任首席技术官，2018年至2021年担任技术与创新副总裁。在这些角色中，他负责领导研发团队追求新技术、化验和系统。Siegrist博士在加州大学欧文分校获得生物医学工程学博士和理学硕士学位，在加州大学洛杉矶分校获得电气工程学学士学位。
Jonathan P. Siegrist,served in various senior R&D positions during his tenure at Cepheid, a molecular diagnostics company, since 2011, including as Chief Technology Officer and Head of Assay R&D from December 2023 to October 2024, as Chief Technology Officer from 2021 to 2023, and as Vice President, Technology & Innovation from 2018 to 2021. In these roles, he was responsible for leading R&D teams to pursue new technologies, assays and systems. Dr. Siegrist received his Ph.D. and Master of Science in Biomedical Engineering from the University of California, Irvine and his B.S. in Electrical Engineering from the University of California, Los Angeles.- Jonathan P. Siegrist，自2011年起在分子诊断公司Cepheid任职期间担任多个高级研发职位，包括2023年12月至2024年10月担任首席技术官和Assay研发主管，2021年至2023年担任首席技术官，2018年至2021年担任技术与创新副总裁。在这些角色中，他负责领导研发团队追求新技术、化验和系统。Siegrist博士在加州大学欧文分校获得生物医学工程学博士和理学硕士学位，在加州大学洛杉矶分校获得电气工程学学士学位。
- Jonathan P. Siegrist,served in various senior R&D positions during his tenure at Cepheid, a molecular diagnostics company, since 2011, including as Chief Technology Officer and Head of Assay R&D from December 2023 to October 2024, as Chief Technology Officer from 2021 to 2023, and as Vice President, Technology & Innovation from 2018 to 2021. In these roles, he was responsible for leading R&D teams to pursue new technologies, assays and systems. Dr. Siegrist received his Ph.D. and Master of Science in Biomedical Engineering from the University of California, Irvine and his B.S. in Electrical Engineering from the University of California, Los Angeles.
- Brian J. Blaser
Brian J. Blaser，2012年-至今，他担任负责诊断产品的高级副总裁兼首席财务官。2010年至2012年，他担任负责诊断的高级副总裁。2008年至2010年，负责诊断的副总裁。2008年，他被当选为企业主管。
Brian J. Blaser,2012 to present - Executive Vice President, Diagnostics Products. 2010 to 2012 - Senior Vice President, Diagnostics. Elected Corporate Officer - 2008.- Brian J. Blaser，2012年-至今，他担任负责诊断产品的高级副总裁兼首席财务官。2010年至2012年，他担任负责诊断的高级副总裁。2008年至2010年，负责诊断的副总裁。2008年，他被当选为企业主管。
- Brian J. Blaser,2012 to present - Executive Vice President, Diagnostics Products. 2010 to 2012 - Senior Vice President, Diagnostics. Elected Corporate Officer - 2008.